News | Heart Failure | June 24, 2015

Scott & White Memorial Uses CardioMEMS HF System to Help Heart Failure Patients

Hospital is sixth in Texas to adopt new remote monitoring device for heart failure

CardioMEMS, Scott & White Memorial, Texas, heart failure, remote monitoring

June 24, 2015 ­- Scott & White Memorial – Temple for the first time implanted a new miniaturized, wireless monitoring sensor to help manage heart failure (HF). Scott & White Memorial is one of six hospitals in Texas and the first hospital in the Baylor Scott & White Health system to offer the device.

"We are always looking for new and innovative ways to treat our patient's disease process and improve outcomes for heart failure patients," said Robert Scott III, M.D., director for advanced heart failure at Scott & White Memorial. "This device will give us the ability to anticipate problems with our patients before they occur, decreasing their chance of being re-admitted to the hospital, and improving their quality of life."

Memorial implemented the CardioMEMS HF System, a U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions.

The device is a sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure. Once implanted, the device can measure and transmit PA pressure from the patient back to their healthcare team. Elevation in PA pressure appears even before changes in weight and blood pressure in the patient, which are traditionally used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their healthcare providers allowing for personalized and proactive management to reduce the likelihood of hospitalization and onset of debilitating symptoms.

"Heart failure can rob patients' quality of life and frequently results in repeated hospitalizations," said John Erwin III, M.D., cardiologist at Scott & White Memorial. "We think that we can provide significantly improved quality of life by partnering with the patient in acting preventatively as opposed to responding when an adverse event occurs."

For more information:

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Overlay Init